Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

PAINS (Pan-Assay INterference compounds)

  • What are PAINS?
  • Pan-Assay INterference compounds
  • Frequent hitters, False positives, Non-specifics
  • Use multiple, different sites on enzyme

Widespread in biochemical HI enzyme activity assays

  • “Painsare unpleasant feelings often caused by intense or damaging stimuli

Often not recognised as non-specific ⇒ Confusion & wasted time

Chemical Con Artists

Adapted from Baell & Walters Nature 513, 481–483

Many mechanisms

  • Compound and/or its impurities
  • e.g. heavy metals, reactive contaminants
  • Technology interference
  • Fluorescence quench
  • Form molecular aggregates
  • Redox
  • Generate reactive species
  • Reactive
  • Promote denaturation by binding unfolded protein

Identification Guidelines

  • IC50 > 3µM
  • Steep concentration-inhibition curve (super stoichiometric)
  • Non-competitive
  • Irreversible
  • Time-dependent
  • Active in unrelated screens
  • Sensitive to detergent (aggregators)
  • No comparable activity in orthogonal assay
  • Assay with different physical basis: e.g. binding v. enzyme activity
  • A known or predicted PAIN structure
  • Flat SAR


  • Don’t remove from screening set
  • Some PAINS are potent drugs and hits
  • Chelators
  • To remove heavy metal impurities
  • Detergent
  • To disrupt aggregates
  • Check with DLS
  • Reductant
  • To mop up oxidants
  • Ensure enzyme is stable
  • FTSA to ID optimal conditions for stability (buffer, pH, ionic strength etc.)
  • Expect low hit rate for known non-specifics

Lysine-Specific Demethylase 1 Inhibitor

  • Epigenetic target
  • Primary screen
  • H2O2 detection: peroxidase-coupled to resorufin fluorescence
  • 2 hit series identified from HTS
  • Some SAR…………


Hit Identification


Deconstruct LSD1 H2O2 Assay

  • Peroxidase interferes with compound inhibition of LSD1
    • Primary HTS as parallel LSD1/Peroxidase assay
    • Co-addition to enzyme/substrate and product detection reagents
  • Re-formatted as serial 2-step assay for comparison


A Generic PAIN-Free Screening Plan?

  • Key elements
    • PAIN primary assay
    • Binding ≡ Biochemical
    • Structure with activity
    • SAR
    • MOI
  • Multidisciplinary
    • Bioscience
    • Biophysics
    • Chemistry

Position Statement

  • Aim to identify and avoid PAINS in…..
    • Early drug discovery
    • Publications on new hits
  • Keep PAINS in screening sets and flagged
    • Use prospective tools to identify PAIN risk
  • Develop a robust PAIN assay cascade specific to target
    • Primary screen (to avoid PAINs)
    • Orthogonal screen (enzyme binding and activity)
  • SAR
    • Confirm structure and activity
    • Early synthetic chemistry at risk to increase SAR confidence
  • MOI
    • Once hit series structure/activity confirmed
  • Share the PAIN
    • PAIN management best practice & learning

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.